Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: A multicenter, randomized, double-blind, vehicle-controlled trial - 28/07/11
, Kristina Gensch, MD b, Merle Haust, MD b, Stefan W. Schneider, MD c, Gisela Bonsmann, MD a, Noemi Gaebelein-Wissing, MD d, Percy Lehmann, MD d, Annette Wons, MD a, Peter Reitmeir, MD e, Vincent Ruland a, Thomas A. Luger, MD a, Thomas Ruzicka, MD f
Reprint requests: Annegret Kuhn, MD, Department of Dermatology, University of Muenster, Von-Esmarch-Strasse 58, D-48149 Muenster, Germany.Abstract |
Background |
Topical calcineurin inhibitors are licensed for the treatment of atopic dermatitis; however, the efficacy of tacrolimus in cutaneous lupus erythematosus (CLE) has only been shown in single case reports.
Objective |
In a multicenter, randomized, double-blind, vehicle-controlled trial, we sought to evaluate the efficacy of tacrolimus 0.1% ointment for skin lesions in CLE.
Methods |
Thirty patients (18 female, 12 male) with different subtypes of CLE were included, and two selected skin lesions in each patient were treated either with tacrolimus 0.1% ointment or vehicle twice daily for 12 weeks. The evaluation included scoring of clinical features, such as erythema, hypertrophy/desquamation, edema, and dysesthesia.
Results |
Significant improvement (P < .05) was seen in skin lesions of CLE patients treated with tacrolimus 0.1% ointment after 28 and 56 days, but not after 84 days, compared with skin lesions treated with vehicle. Edema responded most rapidly to tacrolimus 0.1% ointment and the effect was significant (P < .001) in comparison to treatment with vehicle after 28 days. Clinical score changes in erythema also showed remarkable improvement (P < .05) after 28 days, but not after 56 and 84 days. Moreover, patients with lupus erythematosus tumidus revealed the highest degree of improvement. None of the patients with CLE demonstrated any major side effects.
Limitations |
The study was limited by the small sample size.
Conclusion |
Explorative subgroup analyses revealed that topical application of tacrolimus 0.1% ointment may provide at least temporary benefit, especially in acute, edematous, non-hyperkeratotic lesions of CLE patients, suggesting that calcineurin inhibitors may represent an alternative treatment for the various disease subtypes.
Le texte complet de cet article est disponible en PDF.Key words : autoimmune disease, calcineurin inhibitors, cutaneous lupus erythematosus, randomized trial, tacrolimus ointment, treatment
Abbreviations used : ACLE, CLE, DLE, GCP, IL, ITT, LET, NF-AT, SCLE, SLE
Plan
| This work was supported by Astellas Pharma GmbH and by a Heisenberg Scholarship from the German Research Foundation to A.K. (KU 1559/1-2). |
|
| Conflicts of interest: Dr Kuhn has received honoraria from Astellas Pharma GmbH, Munich, Germany, for presentations. All other authors have declared no conflicts of interest. |
Vol 65 - N° 1
P. 54 - juillet 2011 Retour au numéro
Article précédent
- Sex hormone–binding globulin and risk of hyperglycemia in patients with androgenetic alopecia
- Salvador Arias-Santiago, María Teresa Gutiérrez-Salmerón, Agustín Buendía-Eisman, María Sierra Girón-Prieto, Ramón Naranjo-Sintes
- Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis
- Yasuyuki Fujita, Naoya Yoshioka, Riichiro Abe, Junko Murata, Daichi Hoshina, Hirokatsu Mae, Hiroshi Shimizu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?